Benzinga | Mar 15, 2021 08:22AM EDT

Edesa Biotech Completes Enrollment Of More Than 50% Of Patients I Phase 2 Portion Of Phase 2/Phase 3 Study Of EB05 In COVID-19 Patients

TORONTO, ON / ACCESSWIRE / March 15, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of more than 50% of the patients planned for the Phase 2 portion of its ongoing Phase 2/Phase 3 clinical study evaluating the company's EB05 drug candidate as a single-dose treatment for hospitalized COVID-19 patients with or at risk of developing Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients.